0901ac058053b52fMon, 16 Apr 2012 15:39:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Livensa, testosterone, Revision: 6, Withdrawnhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000630/human_med_000889.jsp&mid=WC0b01ac058001d1240901ac058053c7fcTue, 17 Apr 2012 15:25:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Privigen, human normal immunoglobulin, Revision: 11, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000831/human_med_000993.jsp&mid=WC0b01ac058001d1240901ac058053cef6Tue, 17 Apr 2012 11:02:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Myfenax, mycophenolate mofetil, Revision: 9, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000884/human_med_000914.jsp&mid=WC0b01ac058001d1240901ac058053e110Wed, 18 Apr 2012 09:14:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Xelevia, sitagliptin, Revision: 10, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000762/human_med_001156.jsp&mid=WC0b01ac058001d1240901ac058053fa5eThu, 19 Apr 2012 14:00:00 +0100epar_humanPending EC decision: Glybera , alipogene tiparvovec, Opinion date: 19-Apr-2012http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002145/smops/Negative/human_smop_000235.jsp&mid=WC0b01ac058001d1270901ac0580544b0bMon, 23 Apr 2012 16:00:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Humira, adalimumab, Revision: 27, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000481/human_med_000822.jsp&mid=WC0b01ac058001d1240901ac0580546087Tue, 24 Apr 2012 11:30:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Ioa, nomegestrol acetate / estradiol, Revision: 1, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002068/human_med_001453.jsp&mid=WC0b01ac058001d1240901ac0580548176Fri, 20 Apr 2012 00:00:00 +0100epar_humanPending EC decision: Lantus, insulin glargine, Opinion date: 19-Apr-2012http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000284/smops/Positive/human_smop_000370.jsp&mid=WC0b01ac058001d1270901ac0580548195Fri, 20 Apr 2012 00:00:00 +0100epar_humanPending EC decision: Jakavi, ruxolitinib, Opinion date: 19-Apr-2012http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002464/smops/Positive/human_smop_000363.jsp&mid=WC0b01ac058001d1270901ac058054835cFri, 20 Apr 2012 00:00:00 +0100epar_humanPending EC decision: Rienso, ferumoxytol, Opinion date: 19-Apr-2012http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002215/smops/Positive/human_smop_000364.jsp&mid=WC0b01ac058001d1270901ac05805483a9Fri, 20 Apr 2012 09:30:00 +0100epar_humanPending EC decision: Optisulin, insulin glargine, Opinion date: 19-Apr-2012http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000309/smops/Positive/human_smop_000369.jsp&mid=WC0b01ac058001d1270901ac058054857dMon, 23 Apr 2012 00:00:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Cyanokit, hydroxocobalamin, Revision: 5, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000806/human_med_000731.jsp&mid=WC0b01ac058001d1240901ac05805485a3Mon, 23 Apr 2012 09:55:13 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Rivastigmine Actavis, rivastigmine, Revision: 2, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002036/human_med_001460.jsp&mid=WC0b01ac058001d1240901ac05805485c9Mon, 23 Apr 2012 10:02:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Matever, levetiracetam, Revision: 2, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002024/human_med_001489.jsp&mid=WC0b01ac058001d1240901ac0580548603Mon, 23 Apr 2012 11:30:35 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Sabervel, irbesartan, Revision: 0, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002510/human_med_001556.jsp&mid=WC0b01ac058001d1240901ac058054860bMon, 23 Apr 2012 12:09:09 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Sepioglin, pioglitazone, Revision: 0, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002021/human_med_001525.jsp&mid=WC0b01ac058001d1240901ac0580548661Mon, 23 Apr 2012 15:15:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Zebinix, eslicarbazepine acetate, Revision: 5, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000988/human_med_001172.jsp&mid=WC0b01ac058001d1240901ac058054866aMon, 23 Apr 2012 15:30:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Exalief, eslicarbazepine acetate, Revision: 5, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000987/human_med_000776.jsp&mid=WC0b01ac058001d1240901ac058054867eMon, 23 Apr 2012 17:17:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Grepid, clopidogrel, Revision: 6, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001059/human_med_000812.jsp&mid=WC0b01ac058001d1240901ac0580548737Tue, 24 Apr 2012 10:33:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Azilect, rasagiline, Revision: 11, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000574/human_med_000667.jsp&mid=WC0b01ac058001d1240901ac0580548747Tue, 24 Apr 2012 10:40:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Betaferon, interferon beta-1b, Revision: 21, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000081/human_med_000673.jsp&mid=WC0b01ac058001d1240901ac058054875fTue, 24 Apr 2012 10:53:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Neupro, rotigotine, Revision: 13, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000626/human_med_000926.jsp&mid=WC0b01ac058001d1240901ac05805487adTue, 24 Apr 2012 11:00:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Clopidogrel Zentiva (previously Clopidogrel Winthrop), clopidogrel, Revision: 10, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000975/human_med_000717.jsp&mid=WC0b01ac058001d1240901ac05805487b5Tue, 24 Apr 2012 11:02:27 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Leganto, rotigotine, Revision: 2, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002380/human_med_001458.jsp&mid=WC0b01ac058001d1240901ac05805487f7Tue, 24 Apr 2012 11:09:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Rapilysin, reteplase, Revision: 14, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000105/human_med_001011.jsp&mid=WC0b01ac058001d1240901ac0580548817Tue, 24 Apr 2012 11:34:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Xolair, omalizumab, Revision: 11, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000606/human_med_001162.jsp&mid=WC0b01ac058001d1240901ac058054881eTue, 24 Apr 2012 16:08:10 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Benlysta, belimumab, Revision: 2, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002015/human_med_001466.jsp&mid=WC0b01ac058001d1240901ac0580548828Fri, 20 Apr 2012 14:00:00 +0100epar_humanPending EC decision: Forxiga, dapagliflozin, Opinion date: 19-Apr-2012http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002322/smops/Positive/human_smop_000351.jsp&mid=WC0b01ac058001d1270901ac0580549f81Thu, 26 Apr 2012 15:38:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Velcade, bortezomib, Revision: 27, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000539/human_med_001130.jsp&mid=WC0b01ac058001d1240901ac058054bc65Thu, 26 Apr 2012 10:04:42 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Paglitaz, pioglitazone, Revision: 0, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002309/human_med_001477.jsp&mid=WC0b01ac058001d1240901ac058054bc86Thu, 26 Apr 2012 10:07:28 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Pioglitazone Accord, pioglitazone, Revision: 0, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002277/human_med_001491.jsp&mid=WC0b01ac058001d1240901ac058054bce3Thu, 26 Apr 2012 15:06:51 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Pioglitazone Actavis Group, pioglitazone, Revision: 0, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002558/human_med_001520.jsp&mid=WC0b01ac058001d1240901ac058054bd2dThu, 26 Apr 2012 15:17:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Revlimid, lenalidomide, Revision: 16, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000717/human_med_001034.jsp&mid=WC0b01ac058001d1240901ac058054bd4eThu, 26 Apr 2012 16:17:44 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Pioglitazone Actavis, pioglitazone, Revision: 0, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002324/human_med_001526.jsp&mid=WC0b01ac058001d1240901ac058054bd56Thu, 26 Apr 2012 16:23:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Actos, pioglitazone, Revision: 19, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000285/human_med_000624.jsp&mid=WC0b01ac058001d1240901ac0580553712Fri, 04 May 2012 16:46:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Hizentra, human normal immunoglobulin (SCIg), Revision: 2, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002127/human_med_001440.jsp&mid=WC0b01ac058001d1240901ac0580555ae8Thu, 03 May 2012 12:24:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Valdoxan, agomelatine, Revision: 7, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000915/human_med_001123.jsp&mid=WC0b01ac058001d1240901ac0580555b08Thu, 03 May 2012 14:06:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): ViraferonPeg, peginterferon alfa-2b, Revision: 26, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000329/human_med_001142.jsp&mid=WC0b01ac058001d1240901ac0580555b13Thu, 03 May 2012 14:12:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Intelence, etravirine, Revision: 9, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000900/human_med_000844.jsp&mid=WC0b01ac058001d1240901ac0580555bbcThu, 03 May 2012 14:17:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Reyataz, atazanavir sulphate, Revision: 30, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000494/human_med_001035.jsp&mid=WC0b01ac058001d1240901ac0580555c4eThu, 03 May 2012 14:20:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Prezista, darunavir, Revision: 21, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000707/human_med_000988.jsp&mid=WC0b01ac058001d1240901ac0580555c6aThu, 03 May 2012 14:25:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Vidaza, azacitidine, Revision: 7, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000978/human_med_001138.jsp&mid=WC0b01ac058001d1240901ac0580555d4cThu, 03 May 2012 14:33:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Avastin, bevacizumab, Revision: 26, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000582/human_med_000663.jsp&mid=WC0b01ac058001d1240901ac0580555dceThu, 03 May 2012 14:37:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Tyverb, lapatinib, Revision: 12, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000795/human_med_001120.jsp&mid=WC0b01ac058001d1240901ac0580555e46Thu, 03 May 2012 14:58:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Thymanax, agomelatine, Revision: 5, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000916/human_med_001093.jsp&mid=WC0b01ac058001d1240901ac0580555ea3Thu, 03 May 2012 15:35:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Ceplene, histamine dihydrochloride, Revision: 4, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000796/human_med_000691.jsp&mid=WC0b01ac058001d1240901ac0580555eb3Thu, 03 May 2012 15:50:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Aldurazyme, laronidase, Revision: 10, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000477/human_med_000636.jsp&mid=WC0b01ac058001d1240901ac0580555f12Thu, 03 May 2012 15:56:47 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Trobalt, retigabine, Revision: 2, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001245/human_med_001431.jsp&mid=WC0b01ac058001d1240901ac0580555f82Thu, 03 May 2012 16:01:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Zonegran, zonisamide, Revision: 19, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000577/human_med_001183.jsp&mid=WC0b01ac058001d1240901ac0580555f87Thu, 03 May 2012 16:06:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): NeuroBloc, botulinum toxin type B, Revision: 23, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000301/human_med_000927.jsp&mid=WC0b01ac058001d1240901ac0580555f93Thu, 03 May 2012 16:12:14 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Trajenta, linagliptin, Revision: 1, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002110/human_med_001482.jsp&mid=WC0b01ac058001d1240901ac0580555fbbThu, 03 May 2012 16:17:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Thyrogen, thyrotropin alfa, Revision: 15, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000220/human_med_001094.jsp&mid=WC0b01ac058001d1240901ac0580556069Thu, 03 May 2012 16:30:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Abraxane, paclitaxel, Revision: 7, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000778/human_med_000620.jsp&mid=WC0b01ac058001d1240901ac05805560d5Thu, 03 May 2012 16:34:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Glivec, imatinib, Revision: 17, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000406/human_med_000808.jsp&mid=WC0b01ac058001d1240901ac0580556123Thu, 03 May 2012 16:40:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Iressa, gefitinib, Revision: 5, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001016/human_med_000857.jsp&mid=WC0b01ac058001d1240901ac0580556143Thu, 03 May 2012 16:53:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Optimark, gadoversetamide, Revision: 4, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000745/human_med_000953.jsp&mid=WC0b01ac058001d1240901ac05805561b4Thu, 03 May 2012 17:07:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Ketek, telithromycin, Revision: 17, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000354/human_med_000873.jsp&mid=WC0b01ac058001d1240901ac0580556278Thu, 03 May 2012 17:12:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Altargo, retapamulin, Revision: 11, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000757/human_med_000644.jsp&mid=WC0b01ac058001d1240901ac05805562c0Thu, 03 May 2012 17:19:57 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Tobi Podhaler, tobramycin, Revision: 1, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002155/human_med_001401.jsp&mid=WC0b01ac058001d1240901ac05805562f2Fri, 04 May 2012 00:00:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Zutectra, human hepatitis B immunoglobulin, Revision: 3, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001089/human_med_001328.jsp&mid=WC0b01ac058001d1240901ac058055631bFri, 04 May 2012 17:09:43 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Jevtana, cabazitaxel, Revision: 2, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002018/human_med_001428.jsp&mid=WC0b01ac058001d1240901ac05805568fbMon, 07 May 2012 10:36:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Herceptin, trastuzumab, Revision: 18, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000278/human_med_000818.jsp&mid=WC0b01ac058001d1240901ac058055691fMon, 07 May 2012 11:38:26 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Capecitabine Accord, capecitabine, Revision: 0, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002386/human_med_001553.jsp&mid=WC0b01ac058001d1240901ac058055692eMon, 07 May 2012 12:00:37 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Capecitabine Krka, capecitabine, Revision: 0, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002605/human_med_001554.jsp&mid=WC0b01ac058001d1240901ac058055696eMon, 07 May 2012 13:42:32 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Zoledronic acid Actavis, zoledronic acid, Revision: 0, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002488/human_med_001557.jsp&mid=WC0b01ac058001d1240901ac0580556d98Mon, 07 May 2012 15:48:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Competact, pioglitazone / metformin, Revision: 10, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000655/human_med_000720.jsp&mid=WC0b01ac058001d1240901ac0580556e03Mon, 07 May 2012 16:06:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Glubrava (previously Pioglitazone Metformin Hydrochloride Takeda), pioglitazone / metformin, Revision: 7, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000893/human_med_000809.jsp&mid=WC0b01ac058001d1240901ac0580556e0fMon, 07 May 2012 16:19:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Glustin, pioglitazone, Revision: 18, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000286/human_med_000810.jsp&mid=WC0b01ac058001d1240901ac0580556e49Mon, 07 May 2012 17:14:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): ProQuad, measles, mumps, rubella and varicella vaccine (live), Revision: 9, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000622/human_med_000997.jsp&mid=WC0b01ac058001d1240901ac0580556e98Mon, 07 May 2012 17:18:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Zostavax, zoster vaccine (live), Revision: 13, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000674/human_med_001185.jsp&mid=WC0b01ac058001d1240901ac0580557190Thu, 03 May 2012 15:00:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Champix, varenicline, Revision: 17, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000699/human_med_000696.jsp&mid=WC0b01ac058001d1240901ac05805582b5Thu, 10 May 2012 10:00:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Exelon, rivastigmine, Revision: 25, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000169/human_med_000777.jsp&mid=WC0b01ac058001d1240901ac0580558678Tue, 08 May 2012 11:34:34 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Sancuso, granisetron, Revision: 0, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002296/human_med_001552.jsp&mid=WC0b01ac058001d1240901ac05805586ecTue, 08 May 2012 15:55:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Zalasta, olanzapine, Revision: 9, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000792/human_med_001168.jsp&mid=WC0b01ac058001d1240901ac05805586f4Tue, 08 May 2012 16:00:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Dexdor, dexmedetomidine, Revision: 1, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002268/human_med_001485.jsp&mid=WC0b01ac058001d1240901ac058055870bTue, 08 May 2012 16:15:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Tysabri, natalizumab, Revision: 13, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000603/human_med_001119.jsp&mid=WC0b01ac058001d1240901ac0580558fdcFri, 11 May 2012 10:00:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Temozolomide Sandoz, temozolomide, Revision: 4, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001128/human_med_001227.jsp&mid=WC0b01ac058001d1240901ac058055917dThu, 10 May 2012 16:30:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Halaven , eribulin, Revision: 1, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002084/human_med_001427.jsp&mid=WC0b01ac058001d1240901ac058055921bMon, 07 May 2012 00:00:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): PhotoBarr, porfimer sodium, Revision: 9, Withdrawnhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000493/human_med_000978.jsp&mid=WC0b01ac058001d1240901ac058055b13dFri, 11 May 2012 15:11:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Tandemact, pioglitazone / glimepiride, Revision: 8, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000680/human_med_001076.jsp&mid=WC0b01ac058001d1240901ac058055b171Fri, 11 May 2012 15:12:37 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Capecitabine Teva, capecitabine, Revision: 0, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002362/human_med_001555.jsp&mid=WC0b01ac058001d1240901ac058055b17bFri, 11 May 2012 15:16:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Prometax, rivastigmine, Revision: 23, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000255/human_med_000996.jsp&mid=WC0b01ac058001d1240901ac058055c896Wed, 16 May 2012 09:20:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Circadin, melatonin, Revision: 14, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000695/human_med_000701.jsp&mid=WC0b01ac058001d1240901ac058055cd58Wed, 16 May 2012 15:50:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Fablyn, lasofoxifene, Revision: 2, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000977/human_med_000783.jsp&mid=WC0b01ac058001d1240901ac058055cddaWed, 16 May 2012 16:00:00 +0100epar_humanHuman medicines European Public Assessment Report (EPAR): Prolia, denosumab, Revision: 2, Authorisedhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001120/human_med_001324.jsp&mid=WC0b01ac058001d124Pending EC decisions and European Public Assessment Reports (EPARs): Human medicinal productsCopyright: (C) European Medicines Agency1440en-gbWed, 16 May 2012 21:22:51 +0100http://www.ema.europa.euPending EC decisions and European Public Assessment Reports (EPARs): Human medicinal products